Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 ...

Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

Getting seven experiments on the International Space Station requires a really good idea. Like a brand new way to attack ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

A new study reveals that Epstein-Barr virus (EBV) infection exacerbates ulcerative colitis (UC) by driving macrophage ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination ...

Tourmaline Bio (NASDAQ:TRML – Get Free Report) had its price objective lifted by analysts at HC Wainwright from $49.00 to $50.00 in a research report issued on Friday,Benzinga reports. The firm ...

US healthcare conglomerate Johnson & Johnson appears to have a promising IL-23-blocking oral peptide on its hands in the ...

In Europe, these therapies were introduced between 2006 and 2013. The anti-TNF era was followed by the emergence of interleukin (IL) inhibitors, with J&J’s Stelara (ustekinumab) leading the way ...

The following is a summary of “Net albumin leakage in patients in the ICU with suspected sepsis. A prospective analysis using ...